Caregivers hearing about a new Rett syndrome syrup often want one practical answer: what side effects will change daily routines first? Daybue (trofinetide)—also available as Daybue STIX powder packets—is labeled for Rett syndrome in adults and children 2 years and older. Trofinetide is a synthetic analog of the glycine-proline-glutamate (GPE) fragment related to IGF-1 signaling biology; the label states the mechanism in Rett syndrome is unknown. The everyday takeaway is to plan for diarrhea and weight monitoring with the neurology team—not to treat the bottle as a cure or a dosing experiment at home.
What Rett syndrome is, and what Daybue is for
MedlinePlus Genetics describes Rett syndrome as a rare neurodevelopmental condition that almost always affects girls, commonly linked to MECP2 changes, with loss of purposeful hand use, breathing irregularities, seizures, and intensive caregiving needs. MedlinePlus’s Rett syndrome overview underscores that care is multidisciplinary. Daybue is the first FDA-approved therapy specifically labeled for Rett syndrome in the stated age group; it is given by mouth or G-tube on a morning-and-evening schedule the clinic sets by weight. That is a different job from seizure medicines, tone therapies, or nutritional support already on many care plans.
Diarrhea, dehydration, and weight watches
The DailyMed warnings say most patients experience diarrhea. Families are advised to stop laxatives before starting therapy when the prescriber agrees, begin antidiarrheal treatment if diarrhea occurs, increase oral fluids, and notify the care team. Severe diarrhea or suspected dehydration can mean interrupting, reducing, or stopping the medicine under clinician direction. Weight loss is another labeled watch: monitor weight and nutritional status. Vomiting is also listed among clinically important reactions. The clinical program reported diarrhea as a leading reason for discontinuation, and many patients had persistent or recurring diarrhea even with supportive steps—so caregivers should not wait for “it will settle on its own” if stools escalate or intake falls.
Ask the team how school or respite staff should report stool changes, which fluid goals matter on hot days, and when to hold the next morning or evening dose pending a call-back. Keep a simple log of diarrhea days, vomiting, and weekly weight checks so telehealth visits have facts, not guesses.
Questions that change what you notice next. Confirm the product form (ready oral solution versus STIX packets), who measures each administration, what diarrhea severity triggers a same-day call, how weight trends will be tracked, and whether other GI medicines need a temporary pause. Bring the Medication Guide to the next IEP or nursing-plan meeting so aides know this is a Rett-specific peptide-related therapy with GI watches, not a routine vitamin syrup.
Not medical advice.
Sources
- DailyMed: Daybue / Daybue STIX (trofinetide) prescribing information
- MedlinePlus Genetics: Rett syndrome
- MedlinePlus: Rett syndrome
Related reading
- Acthar Gel courses for MS flares and infantile spasms
- Increlex meal timing for severe IGF-1 deficiency
- School care plans when specialty medicines travel with a child
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-11 PT. Not medical advice.